MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is a hematologic malignancy of differentiated plasma cells that accumulate in the bone marrow, where a complex microenvironment made by different cell types supports proliferation, survival, and drug resistance of tumor cells. MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression at posttranscriptional level. Emerging evidence indicates that miRNAs are aberrantly expressed or functionally deregulated in MM cells as the result of multiple genetic or epigenetic mechanisms and that also the tumor microenvironment regulates MM cell functions by miRNAs. Consistently, modulation of miRNA levels in MM cells has been demonstrated to impair their functional interaction with the bone marrow microenvironment and to produce significant antitumor activity even able to overcome the protective bone marrow milieu. This review will describe the most recent findings on miRNA function in the context of MM bone marrow microenvironment, focusing on the therapeutic potential of miRNA-based approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.005 · Cited by 436
RetractedProcessing of primary microRNAs by the Microprocessor complex
Denli, A. M., Tops, B. B. J., Plasterk, R. H. A., Ketting, R. F., & Hannon, G. J. (2004) · Nature · doi:10.1038/nature03049 · Cited by 2,784 · cited 1×
“Depending on the degree of complementarity between the miRNA and its target mRNA, miRNA binding to 3-UTR represses translation or induces deadenylation and mRNA decay [13, 18, 19].”
BackgroundZhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., & Hung, M.-C. (2004) · Nature Cell Biology · doi:10.1038/ncb1173 · Cited by 1,581
A MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · cited 1×
“CD44 being a functional component of cell adhesion-mediated resistance [6], the authors explored the potential involvement of miR-30s in BMM-dependent drug resistance: restoration of miR-30s expression resensitized MM cells to dexamethasone treatment, even when MM cells were cocultured with BMSCs.”
BackgroundLöffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermüller, J., Kretzschmar, A. K., Burger, R., Gramatzki, M., Blumert, C., Bauer, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081133 · Cited by 637 · cited 3×
“miR-15a/-16 Downregulated in MM cells Tumor suppressors in MM cells, reduce growth and migration of MM and ECs and secretion of VEGF in MM cells AKT3 [21, 80, 81, 83]”
BackgroundUmezu, T., Tadokoro, H., Azuma, K., Yoshizawa, S., Ohyashiki, K., & Ohyashiki, J. H. (2014) · Blood · doi:10.1182/blood-2014-05-576116 · Cited by 600 · cited 5×
“Two recent reports demonstrated the involvement of exosomal miRNAs in both MM-MSCSs tumor-promoting activity and MM cell-mediated angiogenic switch [42, 124].”
BackgroundResultInfluentialMicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Pichiorri, F., Suh, S.-S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806202105 · Cited by 563 · cited 8×
“MM cell adhesion to BMSCs also promotes NF-𝜅Bdependent production of BAFF, amember of the TNFprotein superfamily, crucial for the maintenance and homeostasis of normal B-cell development, which confers a survival advantage on MM cells [37, 38] and promotes RANKLindependent osteoclastogenesis [39].”
BackgroundInfluentialGiuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415 · cited 1×
“The TNF receptor ligand superfamily member OPG acts as a decoy receptor of RANKL, thus antagonizing RANK-L binding to RANK and consequently preserving the integrity of bone mass [71, 72].”
BackgroundPathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gullà, A., Rossi, M., Neri, A., Giordano, A., Munshi, N. C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3325 · Cited by 219 · cited 3×
“Using synthetic miR-21 oligonucleotide inhibitors, we observed in vitro and in vivo activity in SCID/NOD mice bearing human MM xenografts. miR-21 inhibitors triggered upregulation of tumor suppressor genes such as PTEN,BTG2, and Rho-B and reduced MM cell proliferation, survival, and clonogenicity in PTEN/AKT-dependent…”
BackgroundSelf-citationHaematological cancer and quality of life: a systematic literature review
Allart-Vorelli, P., Porro, B., Baguet, F., Michel, A., & Cousson-Gélie, F. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.29 · Cited by 174 · cited 1×
“After non-Hodgkin lymphoma, MM represents the second most common hematologic disease accounting for more than 10% of all hematologic cancers and 2% of annual cancer-related deaths [2].”
BackgroundEvidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107
Human bone marrow myeloma cells express RANKL.
Sezer, O., Heider, U., Jakob, C., Eucker, J., Possinger, K., & Roodman, G. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.353 · Cited by 104
Wang, X., Li, C., Ju, S., Wang, Y., Wang, H., & Zhong, R. (2011) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.591004 · Cited by 103
Berenstein, R., Blau, O., Nogai, A., Waechter, M., Slonova, E., Schmidt-Hieber, M., Kunitz, A., Pezzutto, A., Doerken, B., & Blau, I. W. (2015) · BMC Cancer · doi:10.1186/s12885-015-1078-3 · Cited by 44
Shen, X., Guo, Y., Yu, J., Qi, J., Shi, W., Wu, X., Ni, H., & Ju, S. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-015-0355-4 · Cited by 37 · cited 1×
“furthermore, they observed inhibition ofMMcell growth and survival, as well as an enhanced sensitivity of MM cells to bortezomib treatment [79].”
Background
Cited by
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
Amodio, N., Raimondi, L., Juli, G., Stamato, M. A., Caracciolo, D., Tagliaferri, P., & Tassone, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0606-4 · Cited by 348
Self-citationMaiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
“MiRNAs have been recognized as essential performers in myeloma cells’ interactions with the BM microenvironment, and specifically with MSCs [52,53].”
BackgroundAllegra, A., Casciaro, M., Barone, P., Musolino, C., & Gangemi, S. (2022) · Cancers · doi:10.3390/cancers14112597 · Cited by 19
“They extended the overall survival of treated mice [113], indicating the anti-MM capacity of the miR-199a-5p replacement approach in affecting the hypoxic BM milieu in vivo [114].”
BackgroundNon-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Raimondi, L., De Luca, A., Giavaresi, G., Raimondo, S., Gallo, A., Taiana, E., Alessandro, R., Rossi, M., Neri, A., Viglietto, G., et al. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030037 · Cited by 16
Self-citation
Metadata
- Authors
- Raimondi, L., De Luca, A., Morelli, E., Giavaresi, G., Tagliaferri, P., Tassone, P., & Amodio, N.
- Venue
- BioMed Research International
- Publisher
- Hindawi Limited
- Published
- 2016
- Volume
- 2016
- Pages
- 1-12
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2222732652
- Cited by
- 56
- References
- 17
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.